Reviewer's report
Title:Cost and burden of gastroesophageal reflux disease among patients with
persistent symptoms despite proton pump inhibitor therapy: an observational
study in France
Version: 1Date:14 October 2012
Reviewer: Tomohiko Shimatani
Reviewer's report:
In this manuscript, the authors presented the results of the REMAIN France
study, i.e., the treatment pathways, resource utilization, costs, symptoms and
HRQL in European patients with GERD who were newly identified as partial
responders to optimized PPI therapy. The study was uniquely performed and the
results were well discussed. The reviewer considered that no serious problems
were found, however, it contains some questions as follows.
1) Were the results of this study different between proton pump inhibitor users
and other drug users?
2) Do the doses of proton pump inhibitors, i.e., half dose or full dose, affect these
results?
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
None declared.
Reviewer's report
Title:Cost and burden of gastroesophageal reflux disease among patients with
persistent symptoms despite proton pump inhibitor therapy: an observational
study in France
Version: 1Date:14 October 2012
Reviewer: Tomohiko Shimatani
Reviewer's report:
In this manuscript, the authors presented the results of the REMAIN France
study, i.e., the treatment pathways, resource utilization, costs, symptoms and
HRQL in European patients with GERD who were newly identified as partial
responders to optimized PPI therapy. The study was uniquely performed and the
results were well discussed. The reviewer considered that no serious problems
were found, however, it contains some questions as follows.
1) Were the results of this study different between proton pump inhibitor users
and other drug users?
2) Do the doses of proton pump inhibitors, i.e., half dose or full dose, affect these
results?
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
None declared.
Please review this paper.
user
Reviewer's report
Title:Cost and burden of gastroesophageal reflux disease among patients with
persistent symptoms despite proton pump inhibitor therapy: an observational
study in France
Version: 1Date:14 October 2012
Reviewer: Tomohiko Shimatani
Reviewer's report:
In this manuscript, the authors presented the results of the REMAIN France
study, i.e., the treatment pathways, resource utilization, costs, symptoms and
HRQL in European patients with GERD who were newly identified as partial
responders to optimized PPI therapy. The study was uniquely performed and the
results were well discussed. The reviewer considered that no serious problems
were found, however, it contains some questions as follows.
1) Were the results of this study different between proton pump inhibitor users
and other drug users?
2) Do the doses of proton pump inhibitors, i.e., half dose or full dose, affect these
results?
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
None declared.
assistant